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A hallmark of Alzheimer’s disease (AD) is the accu-
mulation of plaques of Ab 1–40 and 1–42 peptides,
which result from the sequential cleavage of APP
by the b and g-secretases. The production of Ab
peptides is avoided by alternate cleavage of APP
by the a and g-secretases. Here we show that
production of b-amyloid and plaques in a mouse
model of AD are reduced by overexpressing the
NAD-dependent deacetylase SIRT1 in brain, and
are increased by knocking out SIRT1 in brain.
SIRT1 directly activates the transcription of the
gene encoding the a-secretase, ADAM10. SIRT1 de-
acetylates and coactivates the retinoic acid receptor
b, a known regulator of ADAM10 transcription.
ADAM10 activation by SIRT1 also induces the Notch
pathway, which is known to repair neuronal damage
in the brain. Our findings indicate SIRT1 activation is
a viable strategy to combat AD and perhaps other
neurodegenerative diseases.
AR
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder
affecting up to one-third of individuals reaching the age of 80
(Tanzi and Bertram, 2005). It displays a stereotypical brain
pathology; deposition of plaques of amyloid beta (Ab) peptides
and phosphorylation and tangles of the neurofibrillar protein t
(Hardy and Selkoe, 2002). Affected individuals suffer neurolog-
ical damage resulting in memory loss, cognitive, and functional
decline and death.
Insight into the etiology of AD has come from studies of the
rare familial form of early onset AD (Selkoe, 1997). Dominant
mutations have been found in the gene encoding the neuronal
membrane protein amyloid precursor protein (APP), which can
be cleaved in two sequential steps by the b- and g-secretases
to generate Ab 1–40 and 1–42 amyloid peptides (Tanzi and
Bertram, 2005). A second class of dominant mutations giving
rise to familial AD fall in genes presenilin 1 and 2 (PSEN1 and 2),
which encode components of the g-secretase (De Strooper,
2007). These findings suggest a pathway of AD in which sequen-
tial cleavage of APP by the b and g-secretases leads to accumu-
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Ab plaques, t tangles, and neurodegeneration.
Interestingly, the production of Ab peptides is avoided by an
alternate APP cleavage pathway mediated by the a-secretase
followed by the g-secretase (Postina et al., 2004). Indeed, a-sec-
retase cleavage of APP has been shown to be protective in AD
models (Mattson, 1997; Kojro and Fahrenholz, 2005). The
a- and g-secretases also sequentially cleave the notch receptor
to generate a notch intracellular domain (NICD) (Kojro and
Fahrenholz, 2005; van Tetering et al., 2009). The NICD activates
nuclear genes, such as HES1 and HES5 to facilitate neurogene-
sis during development and damage repair in adults (Kopan and
Ilagan, 2009; Yoon and Gaiano, 2005; Costa et al., 2005).
ADAM10 encodes the a-secretase (Saftig and Hartmann, 2005;
Fahrenholz et al., 2008), and transcription of this gene is acti-
vated by the retinoic acid receptor (RAR) (Fahrenholz et al.,
2008; Prinzen et al., 2005; Tippmann et al., 2009). Indeed, several
studies suggest a link between retinoic acid (RA) signaling in the
brain and AD (Goodman and Pardee, 2003; Corcoran et al.,
2004; Goodman, 2006).
Sirtuins are NAD-dependent deacetylases that counter aging
and have a wide spectrum of metabolic and stress-tolerance
functions (Sinclair, 2005). Of the seven mammalian sirtuins, the
SIR2 ortholog SIRT1 deacetylates numerous regulatory proteins,
such as PGC-1a, p53, FOXO, HSF, and HIF-2a to trigger resis-
tance to metabolic, oxidative, heat, and hypoxic stress
(Guarente, 2009). SIRT1 has been directly implicated in neuronal
protection against stress in cultured cells (Qin et al., 2006). In
mice, SIRT1 has been shown to protect against neurodegenera-
tion in the p25 overexpressionmodel (Kim et al., 2007), as well as
in Wallerian degeneration slow mice (Araki et al., 2004). More
generally, SIRT1 mediates at least some of the effects of calorie
restriction (Guarente, 2008), a diet reported to protect against
models of neurodegenerative diseases, including AD (Patel
et al., 2005).
Here, we investigate whether SIRT1 levels in brain affect the
Ab plaque formation, pathology, and cognitive decline in AD
mouse model (APPswe/PSEN1dE9 double transgenic). We
show that SIRT1 can suppress AD in a mouse model for this
disease. The induction of brain pathology and behavioral deficits
was mitigated in AD mice overexpressing SIRT1 in brain, and
exacerbated with SIRT1 knocked out in the brain. SIRT1 directly
activates transcription of ADAM10, which encodes the a-secre-
tase by deacetylating RARb. SIRT1 appears to direct APP pro-
cessing toward the a-secretase and away from the b-secretase,
which results in a reduction in the production of toxic b-amyloid
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Apeptides. Furthermore, by activating ADAM10, which is also
known to cleave themembrane-bound notch receptor thus liber-
ating an intracellular domain that activates nuclear genes for
neurogenesis, SIRT1 also activates notch pathway. As a result
of this, SIRT1 helps to mitigate AD by increasing neurogenesis
and neuroprotection that would be a second way besides sup-
pressing b-amyloid production.
RESULTS
Effects of SIRT1 Levels in a Mouse Model of AD
We wished to test whether the levels of SIRT1 in the brain could
influence Ab plaque formation and the accruing pathological and
cognitive decline in a mouse model of AD. We thus employed
a model in which two linked transgenes, encoding the human
APPswe and PSEN1dE9 alleles drive Ab plaque formation and
learning and memory deficits (Jankowsky et al., 2004). Plaques
are evident in this model at 3–5months of age, and they progress
in number and size asmice grow older. In order to test the effects
of increasing SIRT1 in these AD mice, they were crossed to
strainsbearing aSIRT1 transgenic allele (Tg in figures) that results
in overexpression of the protein in the brain by about 2-fold (Bor-
done et al., 2007). Neither the SIRT1 transgene nor the knock-out
allele described below affected expression of the APPswe or
PSEN1dE9 disease genes (not shown). In all experiments, we
compare congenic C57BL/6 littermates by quantifying cortical
plaque number in serial coronal cross sections.
We observed a marked reduction of plaques in 5-month-old
AD transgenic mice overexpressing SIRT1 (AD-Tg) compared
to AD control mice (Figure 1A). Wild-type (WT) mice without
the AD disease genes were free of plaques. In order to inactivate
SIRT1 in the brain, we used brain-specific knock out mice
(BSKO) (Cohen et al., 2009), which lack full length SIRT1 in all
neurons and glia (Figure 1B), but show normal adult brain
morphology (Figure S1A available online). To test the effects of
SIRT1 inactivation, BSKO mice were crossed to AD mice.
Remarkably, AD-BSKO mice all died between 3 and 5 months
of age, whereas AD mice or BSKO mice themselves lived well
past 1.5 years of age (Figure 1C and data not shown). Although
we have not pinpointed the cause of death in AD-BSKO mice,
this synthetic lethality is typically indicative of a strong genetic
interaction between the genes involved, further linking SIRT1
to AD pathogenesis. Consistent with this, AD-BSKO mice dis-
played a marked increase in plaques in 3-month-old mice
compared to AD control mice (Figure 1D).
In order to monitor other features of brain pathology, we as-
sayed for gliosis by immunological quantitation of the glial
marker of inflammation, glial fibrillary acidic protein (GFAP) (Pan-
ter et al., 1985). A progressive increase in cortical GFAP staining
was observed in AD control mice, and this was markedly
reduced in AD-Tg mice and exacerbated in AD-BSKO mice
(Figure 1E). In addition, phosphorylation of t at Ser199 and
Ser399 (Johansson et al., 2006) was evident in ADmice and sup-
pressed in AD-Tg mice (Figures S1B and S1C).
ADmice show age-dependent decline in learning andmemory
(Reiserer et al., 2007), which can be measured with behavioral
tests. In the fear-conditioning test (Bryan et al., 2009), mice
were trained on day 1 by repeated exposure to a tone followed
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on day 2 by a freezing behavior when exposed to the tone
without the shock. AD control mice showed a progressive
decline in performance in this test at 8 and 11 months of
age compared to 4 and 6months of age (Figure 2B). This decline
was clearly suppressed in older, age-matched AD-Tg mice.
Wild-type and SIRT1 transgenic mice without the AD genes
showed roughly normal learning at all ages (Figure 2B).
Conversely, AD-BSKO mice were precociously defective in this
test at 4 months of age, whereas BSKO mice without the AD
disease genes performed similar to wild-type mice (Figure 2C).
In the Morris water maze test, mice are trained to use visual
cues to find a submerged platform in an opaque pool (Bryan
et al., 2009). By determining the time required to find the platform
(escape latency) as a function of days of training, we observed
a marked decline in performance in 8- and 10-month-old AD
mice compared to 4 month olds (Figure 2D). This decline was
significantly mitigated in AD-Tg mice. In mice without the AD
genes, the SIRT1 transgene had no effect at any ages
(Figure 2E), indicating that the suppression of decline in AD-Tg
mice is not due to an inherent increase in learning and memory
in SIRT1 overexpressing mice. As in the fear conditioning test,
AD-BSKO mice displayed a precocious defect at 4 months of
age (Figure 2F). We observed no differences in swim speed in
any mice tested (Figure S1D).
SIRT1 Activates a-Secretase and Reduces Production
of b-Amyloid
Because Ab plaques were reduced in SIRT1 transgenic mice, we
quantitated Ab levels in brains of AD mice overexpressing or
lacking SIRT1 by ELISA. Strikingly, Ab 1–42 levels were substan-
tially reduced in AD-Tg mice and enhanced in AD-BSKO mice
(Figure 3A). SIRT1 affected Ab 1–40 in a likemanner (Figure S2A).
The reduction in Ab levels in SIRT1 overexpressing mice was
largest in 4-month-old mice and grew smaller, but was still
evident, in older mice. A second assay using immunoblotting
also showed similar effects on Ab levels by SIRT1 (Figure S2B).
A reduction of Ab levels by SIRT1 could reflect a reduced
production of the amyloid peptides. To address the potential of
mice to produce Ab, we prepared brain extracts and assayed
the a and b-secretases (Kojro and Fahrenholz, 2005; Fahrenholz
et al., 2008; Rockenstein et al., 2005). Remarkably, AD-Tg mice
showed a doubling of a-secretase activity in 2-, 4-, and 6-month-
oldmice compared to AD-controls (Figure 3B). Conversely, there
was a small but significant reduction in BSKO mice with or
without the AD genes.
In addition, we observed a small decrease in b-secretase
activity (Figure 3C) and BACE1 (b-secretase) RNA (Figure S2C)
in SIRT1 overexpressing mice at all ages. However, because
b-secretase was induced by the progression of disease in AD
mice (Fukumoto et al., 2004), it is likely that the small decrease
in this activity in AD-Tg mice is a secondary consequence of a
slower disease onset and progression. Consistent with this
idea, b-secretase activity (Figure 3C) and BACE RNA levels (Fig-
ure S2C) were higher in AD-BSKO mice compared to AD mice.
Examinationof individualg-secretasesubunitspen2 (FigureS2D),
Aph1a, Aph1b (Figure S2E), and presenilin 1 (Figure S2F) showed
no differences in mice with altered levels of SIRT1.
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Figure 1. SIRT1 Levels Regulate the Pathology in a Mouse Alzheimer’s Disease Model
(A) Cortical frozen sections (six per mouse) of fixed brains from indicatedmice (ages in months [m]) stained with Ab-specific 6E10 antibody. The graph on the right
shows the quantification of the amyloid plaques according to their sizes in APPswe,PSEN1dE9 mice with endogenous SIRT1 (AD) and with a SIRT1 transgene
(AD-Tg), n = 5. Left shows examples of stained samples from these andWTmice. Scale bar represents 50 mm. * indicates p < 0.01 throughout in Student’s t test.
(B) Western blot analysis of SIRT1 expression in wild-type (wt) and SIRT1 brain specific knockout mouse (BSKO) whole brains. Deletion of exon 4 resulted in the
truncated inactive form of SIRT1 in BSKO mice. b-actin served as a loading control.
(C) Survival curve of the percent viability of the AD, BSKO and AD-BSKOmice. n = 47 for AD-BSKO and BSKO and n = 45 for AD mice. Both BSKO and AD mice
showed 100% viability.
(D) Cortical frozen sections of fixed brains from indicated mice stained with Ab-specific 6E10 antibody. The graph on the right shows the quantification of the
amyloid plaques. Scale bar represents 50 mm. n = 5.
(E) Frozen sections of fixed brains from indicated mice stained with GFAP (glial fibrillary acidic protein) antibody for gliosis. The graph on the right shows the
quantification of the GFAP staining. Scale bar represents 50 mm.
The analysis was carried out using Student’s t test. Significant differences are shown by single asterisk (*) indicating p < 0.01. Error bars represent SEM. See also
Figure S1.
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directing APP processing toward the a-secretase. To obtain
further evidence for this hypothesis, we quantitated two of the322 Cell 142, 320–332, July 23, 2010 ª2010 Elsevier Inc.products of a-secretase cleavage. First, a-secretase generates a
large a-fragment ectodomain of APP (Figure 3D), whichmigrates
slightly faster than APP in a gel (Lesne´ et al., 2006; Vieira et al.,
Figure 2. SIRT1 Improves the Behavioral Phenotype of Alzheimer’s Disease Mouse Model
(A) Schema of the fear conditioning experiment.
(B) The graph shows the total percentage of freezing (on day 2) of theWT, Tg, AD, and AD-Tgmice of the indicated ages across the entire 5 min tone retrieval test.
n = 10–15 for each bar.
(C) The graph shows the total percentage of freezing of the WT, BSKO, AD, and AD-BSKO mice at 4 months of age across the entire 5 min tone retrieval test.
n = 10–15.
(D) Morris water maze experiment (D-F). Escape latency (time to find the platform) was plotted for 7 days for 11-, 8-, and 4-month-old AD and AD-Tg mice.
n = 6–12.
(E) Escape latency plotted over 7 days for 11-, 8-, and 4-month-old Tg and WT mice. n = 6–12.
(F) Escape latency plotted over 7 days for 4-month-old WT, BSKO, AD and AD-BSKO mice. n = 6–12.
The analysis was carried out using Student’s t test. Significant differences are shown by single asterisk (*) indicating p < 0.01. Error bars represent SEM. See also
Figure S1.
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Figure 3. SIRT1 Reduces Ab Levels and Increases a-Secretase Activity
(A) Ab 1-42 levels measured using ELISA from the whole brains of the indicated mice. n = 6 for each bar.
(B) a-secretase activity from the whole brains of indicated mice using an activity assay. n = 6. AFU, arbitrary fluorescence units.
(C) b-secretase activity in the whole brains of indicated mice. n = 6.
(D) The scheme of the proteolytic processing of APP. Ab 40/42, amyloid b peptide with 40 (Ab 1-40), or 42 amino acid residues (Ab 1-42); APP, amyloid precursor
protein; AICD, APP intracellular domain; APPa, soluble APP after a-secretase cleavage (a-fragment); APPb, soluble APP after b-secretase cleavage; C99,
C-terminal fragment of APP of 99 amino acids after b-secretase cleavage; C83, C-terminal fragment of APP of 83 amino acids after a-secretase cleavage
(a-CTF); P3, N-terminal fragment of C83 after a-secretase cleavage.
(E) Western blotting of the whole brains of indicated mice of 6 months of age using 6E10 antibody. b-actin serves as the loading control. Quantification of the
APPa/APP ratio is shown on the right as percent of control.
(F) Western blotting of the whole brains of indicated mice of 6 months of age using APP C-terminal antibody. b-actin serves as the loading control. Quantification
of the a-CTF is shown on the right as percent of control.
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A2009). The ratio of a-fragment to APP was clearly increased in
AD-Tg mice and decreased in AD-BSKO mice (Figure 3E). We
have also determined the levels of a-fragment by using an a-
fragment-specific antibody (APPa antibody), and observed that
the levels of a-fragment in AD-Tg mice is increased compared
to AD mice (Figure S2G). Second, the other product of APP
cleavage by a-secretase is a fragment termed a-CTF (Lesne´
et al., 2006; Vieira et al., 2009) (Figure 3D), and again, levels of
this protein were increased in AD-Tg mice (Figures 3F and 3H,
performed by using two different antibodies). We have also ana-
lyzed the products of APP cleavage by b-secretase (Figure 3D),
b-fragment, and b-CTF. Both were decreased in AD-Tg mice
compared to AD mice (Figures 3G and 3H). Together, all of the
above findings indicate that a-secretase is activated by SIRT1.
SIRT1 Activates ADAM10 Transcription and Notch
Pathway
We next determined RNA levels in the brain of ADAM10, which
encodes the a-secretase (Saftig and Hartmann, 2005; Fahren-
holz et al., 2008) and found a significant increase in SIRT1 over-
expressing mice with or without the AD disease genes
(Figure 4A). Conversely, AD-BSKO mice showed a significant
decrease in ADAM10 RNA. We also observed elevated levels
of ADAM10 and its precursor ADAM10-P in SIRT1 overexpress-
ing mice with (Figure 4B, left panel; Figure S3A) or without
(Figure 4B, middle panel) the AD genes, and decreased levels
in AD-BSKO mice (Figure 4B, right panel). The ADAM10 homo-
logs ADAM 9 and ADAM 17 (Saftig and Hartmann, 2005) did
not show clear changes in SIRT1 overexpressing or BSKO
mice with or without the AD disease genes (Figure S3B).
What might be the biological relevance of SIRT1 activation of
ADAM10? This protease is known to cleave the notch receptor
to release a notch intracellular domain (NICD), which activates
transcription of genes involved in neurogenesis and patterning
during embryonic development and the maintenance of brain
function in adults (Yoon and Gaiano, 2005; Costa et al., 2005).
To determine whether SIRT1 regulates the notch pathway in
adults, we first quantitated levels of the NICD in brain extracts.
SIRT1 Tg mice with or without the AD disease genes showed
a significant elevation in NICD levels in AD-Tg mice compared
to AD controls (Figure 4C). Moreover, transcription of the notch
nuclear target genes HES1 and HES5 (Kopan and Ilagan, 2009;
Yoon and Gaiano, 2005) were also significantly elevated in AD-
Tg mice compared to AD mice (Figure 4D).
Activation of ADAM10 Depends on Deacetylase Activity
of SIRT1 and Retinoic Acid
The above findings suggest that SIRT1 is a positive activator of
ADAM10 transcription. Consistent with this surmise, chromatin
immunoprecipitation assays revealed direct interaction of
E
R(G) Western blotting of the whole brains of indicated mice of 6 months of age us
APPb fragment is shown on the right as percent of control.
(H) Western blotting of the whole brains of indicated mice of 6 months of age usin
ure 3F that can detect both a-CTF and b-CTF. b-actin serves as the loading contr
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The analysis was carried out using Student’s t test. Significant differences are sho
Figure S2.SIRT1 with a specific region of the ADAM10 promoter 467 to
30 but not 2100 to 1900 (Figure 5A; Figure S4A). This
gene-proximal region of ADAM10 is where the RAR is known
to bind and activate transcription (Prinzen et al., 2005). Cellular
effects of RA are mediated by the RARs and retinoic X receptors
(RXRs), which form heterodimers and bind to retinoic acid
response element (RAREs) to activate gene expression
(Mangelsdorf and Evans, 1995).
We next investigated themechanism of ADAM10 activation by
SIRT1 in cultured cells. SIRT1 or the catalytically inactive and
dominant negative mutant His363-Tyr (SIRT1HY) were ex-
pressed in mouse embryo fibroblasts (MEFs) from SIRT1+/+
and SIRT1/ embryos (Figure S4B) and endogenous ADAM10
RNA (Figure 5B) or NICD levels (Figure 5C) were quantitated.
Expression of SIRT1 but not SIRT1HY increased levels of
ADAM10 RNA and NICD protein in SIRT1/ MEFs, indicating
that the deacetylase activity of SIRT1 is required for ADAM10
activation. Further, addition of RA also increased ADAM10
RNA and NICD protein in SIRT1+/+ but not SIRT1/ MEFs,
and this activation was further enhanced by SIRT1 and blocked
by SIRT1-HY. These findings suggest that the RAR is the target
of SIRT1 activation of ADAM10. To bolster this claim, we also
expressed SIRT1 or SIRT1-HY in N2A neuroblastoma cells
(Figure S4C). Expression of SIRT1 but not SIRT1-HY activated
ADAM10 RNA (Figure S4D) and NICD protein levels (Figure S4E)
in N2A cells. Further, addition of RA also increased ADAM10
RNA and NICD protein, and this activation was further enhanced
by SIRT1 and blocked by SIRT1-HY as in MEF cells.
SIRT1 Deacetylates Retinoic Acid Receptor b
SIRT1 is known to deacetylate numerous mammalian transcrip-
tion factors (Donmez and Guarente, 2010). To further investigate
the relationship between SIRT1 and the RAR, we studied a lucif-
erase reporter driven by the RARE in MEFs (Figure 6A). Lucif-
erase levels were activated by SIRT1 overexpression and
reduced in SIRT1/MEFs. Moreover, addition of RA-stimulated
luciferasewhile preserving the differences in SIRT1 overexpress-
ing and SIRT1/ MEFs. In contrast, the RAR antagonist LE 135
(Li et al., 1999) blocked activity in all cases. These findings clearly
indicate that SIRT1 coactivates the RAR. Next, we carried out
immunoprecipitation of endogenous SIRT1 on antibody-coated
beads (Figure 6B). We observed coimmunoprecipitation of
endogenous RARb, the major isoform in the brain (Mangelsdorf
and Evans, 1992; Dolle´ et al., 1990). As a specificity control,
we checked LXR levels (another nuclear receptor) in the immu-
noprecipitates and observed none (Figure S5A). Finally, we
found that acetylation of endogenous RARb was enhanced in
SIRT1/ cells and reduced in SIRT1 overexpressing cells,
further indicating that SIRT1 coactivates RARb by deacetylating
it (Figure 6C). Also, acetylation of endogenous RARb was
EDing APPb antibody. b-actin serves as the loading control. Quantification of the
g a different APP C-terminal antibody (see Experimental Procedures) from Fig-
ol. Quantification of the a-CTF and b-CTF are shown on the right as percent of
wn by single asterisk (*) indicating p < 0.01. Error bars represent SEM. See also
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Figure 4. SIRT1 Increases a-Secretase Levels by Activating ADAM10
(A) ADAM10 RNA levels from whole brains of indicated mice quantified by q-PCR. The numbers on x axis show the age of mice in months. n = 5 for each bar.
(B) Western blotting of whole brains from mice of indicated ages in months (m) and years (y) using ADAM10 antibody. b-actin serves as the loading control.
ADAM10-P shows the unprocessed ADAM10 precursor protein. Quantification of ADAM10-P (top) and ADAM10 (bottom) are shown below each gel as percent
of control.
(C) Western blotting of whole brains from indicated mice using NICD (Notch intracellular domain) antibody. b-actin serves as the loading control. Quantification of
NICD is shown below as percent of control.
(D) HES1 and HES5 RNA levels quantified from whole brains of mice by q-PCR. The numbers on x axis show the age of mice in months. n = 5.
The analysis was carried out using Student’s t test. Significant differences are shown by single asterisk (*) indicating p < 0.01. Error bars represent SEM. See also
Figure S3.
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Figure 5. SIRT1 and RA directly activate ADAM10
(A) Chromatin-immunoprecipitation on whole brains of 6-month-old SIRT1 Tg, AD-Tg, and SIRT1/mice with anti-SIRT1 antibody or IgG. The scheme illustrates
the highest activity region of the ADAM10 promoter and the fragments generated by primers in qPCR assay. q-PCR was performed using primers as indicated
(see Experimental Procedures). SIRT1/ mice were in a mixed genetic background to allow recovery of viable adults (McBurney et al., 2003).
(B) ADAM10 RNA levels quantified by q-PCR from the SIRT1+/+ or SIRT1/MEFs transfected with mSIRT1 or mSIRT1-HY and/or treated with retinoic acid (RA).
(C) NICD levels determined by western blotting from the SIRT1+/+ or SIRT1/ MEFs transfected with mSIRT1 or mSIRT1-HY and/or treated with retinoic acid
(RA). b-actin serves as the loading control. Quantification of NICD levels is shown on the right as percent of control.
The analysis was carried out using Student’s t test. Significant differences are shown by single asterisk (*) indicating p < 0.01. Error bars represent SEM. See also
Figure S4.
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Figure 6. SIRT1 Deacetylates RARb
(A) Luciferase reporter assays of MEFs overex-
pressing SIRT1 (mSIRT1), lacking SIRT1
(SIRT1/), or controls (wt). Cells were transfected
with luciferase reporter driven by the RARE (Reti-
noic Acid Receptor Element). Twenty-four hours
later, cells were incubated with RA (Retinoic
Acid), LE-135, or DMSO for an additional 24 hr
and assayed as described in Experimental Proce-
dures.
(B) Cell lysates from wild-type (wt) and SIRT1/
(SIRT1/) MEFs immunoprecipitated with normal
rabbit serum (NRS) or anti-SIRT1 antibody and
blotted with anti-SIRT1 and anti-RARb antibodies.
The two proteins are shown to interact at endoge-
nous levels.
(C) Cell lysates from wild-type (wt), SIRT1-over-
xpressing (mSIRT1) MEFs, SIRT1/ MEFs, and
SIRT1/ MEFs overexpressing SIRT1 catalytic
mutant HYwere subjected to immunoprecipitation
with anti-RARb antibody or NRS. Immunoprecipi-
tates were analyzed by western blotting with
anti-RARb, anti-RXR, or anti-pan acetylated lysine
(Ac-K) antibodies. Quantification of the acetylation
levels were shown below (see also Figure S5).
(D) A model for the role of SIRT1 in suppressing Ab
production and activating notch pathway. SIRT1
deacetylates RARb, causes RA to bind to RARb-RXR heterodimer that binds to ADAM10 promoter. ADAM10 transcription and protein level is increased and
APP processing is directed toward a-secretase pathway. This will lead to less b-secretase cleavage of APP resulting in less Ab production, fewer b-amyloid pla-
ques, and less gliosis. ADAM10activation bySIRT1also induces theNotchpathway,which is known to repair neuronal damage inbrain, providingneuroprotection.
The analysis was carried out using Student’s t test. Significant differences are shown by single asterisk (*) indicating p < 0.01. Error bars represent SEM. See also
Figure S5.
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in SIRT1/ cells, indicating that catalytic domain of SIRT1 is
required for deacetylation. We did not observe acetylation of
endogenous RARa when identical immunoprecipitation experi-
ments were performed using RARa antibody (Figure S5B), indi-
cating the effects of SIRT1 are specific for RARb.
SIRT1 Suppresses Ab Production Because It Activates
ADAM10
Does the increase in ADAM10 in SIRT1 overexpressing mice
account for the reduction in b-amyloid production? To address
this question, we assayed Ab1–42 produced by N2A neuroblas-
toma cells expressing the APPswe and PSEN1dE9 transgenes
(Borchelt et al., 1996). Overexpression of SIRT1 in these cells
substantially increased ADAM10 (Figure 7B) and reduced Ab
levels (Figure 7A) compared to control cells, analogous to what
we observed in mice. Conversely, silencing ADAM10 with three
different shRNAs alone (Figure 7B) increased Ab (Figure 7A). Of
critical importance, in cells overexpressing SIRT1, ADAM10-
shRNAs reduced ADAM10 to levels of control cells (Figure 7B)
and also prevented the suppression in Ab production by this sir-
tuin (Figure 7A). We also employed scrambled shRNA as control
that did not have any silencing effect on ADAM10 (Figures S6A–
S6C). This finding indicates SIRT1 overexpression reduces Ab
production by increasing ADAM10. Finally, as in the mice, the
reduction of SIRT1 levels (by three different shRNAs 1, 2, and 3)
increased Ab production in these cells (Figures 7A and 7B;
FigureS6D).Asa test for thespecificityof theseADAM10shRNAs,
we showed that their effects were rescued by expressing
E328 Cell 142, 320–332, July 23, 2010 ª2010 Elsevier Inc.ADAM10mutant genes thatwere resistant to shRNA1oransiRNA
to the ADAM10 30 UTR (Figures S6E and S7A).
Correspondingly, NICD levels (Figure 7C) and expression of
the notch targets HES1 (Figure 7D) and HES5 (Figure S7B)
were increased by SIRT1 overexpression and decreased by
shRNA for SIRT1 or ADAM10 in these cells. Most importantly,
shRNA for ADAM10 reversed the increase in notch activity in
SIRT1 overexpressing cells (Figures 7C and 7D). The above anal-
ysis draws a causal link between SIRT1 expression, ADAM10
activation, and Ab suppression. A recent report showed that
SIRT1 could affect a-secretase activity in cultured cells by inhib-
iting expression of the rho-associated protein kinase ROCK1
(Qin et al., 2006). However, we observed no differences in
ROCK1 levels in mice with altered levels of SIRT1 (Figure S7C).
In order to show that RARb activation by SIRT1 suppresses Ab
production, we treated N2A neuroblastoma cells expressing
the APPswe and PSEN1dE9 transgeneswith RA and RAR antag-
onist LE135. RA decreased Ab production thereby augmenting
the SIRT1 effect, whereas LE135 increased Ab production
thereby blocking the effect of SIRT1 (Figure 7E). These data
show that RARb activation by SIRT1 affects Ab production.
DISCUSSION
Our findings clearly indicate that SIRT1 can suppress AD in
a mousemodel for this disease. The induction of brain pathology
and behavioral deficits in doubly transgenic APPswe/PSEN1dE9
mice was mitigated in mice overexpressing SIRT1 in the brain,
and exacerbated in mice with SIRT1 knocked out in the brain.
Figure 7. SIRT1 Suppresses Ab Production by Activating ADAM10
(A) N2A cells stably overexpressing APPswe/PSEN1dE9 transgenes transfected with SIRT1 (mSIRT1). Twenty-four hours after SIRT1 transfection, cells were
transfected with three different ADAM10-shRNA vectors (1, 2, or 3). N2A cells not overexpressing SIRT1 were also transfected with three different ADAM10-
shRNA vectors (1, 2, or 3) to silence ADAM10. Separately, SIRT1was silenced by three different shRNAs (1, 2, or 3). Forty-eight hours later, Ab 1–42 concentration
in the conditionedmediumwas assessed by ELISA (Experimental Procedures). N2A cells without APPswe,PSEN1dE9 transgenes showed no detectable Ab 1–42
in this assay (not shown).
(B) Western blotting of the extracts of these cells using anti-ADAM10 antibody. Quantification of the ADAM10-P (top) and ADAM10 (bottom) were shown on the
right as percent of control.
(C) Western blotting of the extracts of the cells using anti-NICD antibody. Quantification of the NICD are shown on the right as percent of control.
(D) HES1 RNA levels were determined by qPCR from RNA extracted from cells.
(E) N2A cells stably overexpressing APPswe/PSEN1dE9 were transfected with SIRT1 (mSIRT1). Twenty-four hours later, cells were incubated with RA (Retinoic
Acid), LE-135, or DMSO for an additional 24 hr and assayed by ELISA.
The analysis was carried out using Student’s t test. Significant differences are shown by single asterisk (*) indicating p < 0.01. Error bars represent SEM. See also
Figures S6 and S7.
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DSIRT1 appears to direct APP processing toward the a-secretase
and away from the b-secretase, which results in a reduction in
the production of toxic b-amyloid peptides (Figure 6D). Indeed,
SIRT1 directly activates transcription of ADAM10, whichencodes the a-secretase. ADAM10 is also known to initiate acti-
vation of the notch pathway by cleaving the membrane-bound
notch receptor thus liberating an intracellular domain that acti-
vates nuclear genes for neurogenesis (Costa et al., 2005;Cell 142, 320–332, July 23, 2010 ª2010 Elsevier Inc. 329
Hartmann et al., 2001). Studies in neuroblastoma cells show that
the suppression of Ab production by SIRT1 is prevented by
normalizing ADAM10 levels with specific shRNAs. Thus we
conclude that the activation of ADAM10 by SIRT1 is mechanisti-
cally linked to Ab suppression.
The mechanism of activation of ADAM10 by SIRT1 appears to
be deacetylation of the RARb, which is known to activate
ADAM10 transcription. SIRT1 but not a catalytically inactive
mutant activated ADAM10 transcription and the notch pathway
in neuroblastoma cells and MEFs. Moreover, SIRT1 coactivated
RAR in reporter assays, bound to the receptor at endogenous
levels, and determined its acetylation level. SIRT1 has also
been shown to deacetylate and regulate other members of the
nuclear receptor family, such as LXR, PPARg, PPARa, and the
androgen receptor.
We can not be certain that the reduction in Ab production in
SIRT1 overexpressing mice is the sole mechanism conferring
protection against memory decline in AD mice. First, activation
of notch or perhaps other pathways by the increase in
ADAM10 may also contribute to AD protection, because this
pathway mediates repair in response to neuronal damage in
the brain (Vieira et al., 2009; Mangelsdorf and Evans, 1995).
Second, SIRT1 may also increase stress tolerance in neurons
of the AD brain. Third, RAR targets other than ADAM10 may
play some role in protection because RAR signaling is known
to be disrupted in the AD brain (Goodman and Pardee, 2003;
Corcoran et al., 2004; Goodman, 2006). However, we can be
confident that the increase in ADAM10 and resulting reduction
in Ab will benefit AD mice. Indeed, ADAM10 has been shown
to prevent amyloid plaque formation and hippocampal behav-
ioral defects in AD mice (Postina et al., 2004). Further,
ADAM10 mutations have been associated with a reduction in
a-secretase in familial late-onset AD (Kim et al., 2009).
Mutations that severely reduce notch signaling result in
embryonic lethality, because of a deficit in brain development
(Yoon and Gaiano, 2005). Brain-specific SIRT1 KOmice activate
cre in early embryos, yet are born in expected numbers and do
not display any detectable defects in adult brain morphology
or in performing behavioral tasks. It is possible that the reduction
of notch signaling in the absence of SIRT1 is not sufficiently
severe to cause dysfunction during embryonic development.
Alternatively, the activation of notch by SIRT1 may have evolved
for maintenance of the adult brain, rather than development.
SIRT1 has been implicated in protection against metabolic
syndrome and diabetes, and sirtuin activators may offer prom-
ising new treatments for these increasingly common disorders
(Milne et al., 2007). Recent studies also implicate SIRT1 in tumor
protection, at least in somemousemodels (Firestein et al., 2008).
Our findings indicate that another important disease of aging,
Alzheimer’s Disease, is also mitigated by genetic activation of
SIRT1. It may therefore be critically important to develop sirtuin
activators tailored to cross the blood brain barrier to treat neuro-
degenerative diseases. The broad efficacy of SIRT1 activation in
treating diseases of agingmay derive from evolutionary selection
for tissue maintenance to allow for delayed reproduction in the
face of dietary or other stressors. The challenge is to harness
this protection pharmacologically in a developed world, in which
many of these stressors no longer exist.
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Mouse Strains
All mice used were in congenic C57Bl/6 except SIRT1/mice for CHIP assay.
Double transgenic (APPswe,PSENdE9) ADmousemodel was purchased from
Jackson Laboratory. SIRT1 transgenic mice have been described previously
(Bordone et al., 2007). SIRT1 brain-specific knockout mice were generated
by crossing a SIRT1 allele containing a floxed exon 4 (Cheng et al., 2003)
with Cre-expressing mice driven by the brain-specific nestin promoter (Cohen
et al., 2009). All mice were housed at controlled temperature (25C) and
12:12 hr light/dark cycle.
Immunohistochemistry
Mice were perfused with 4% paraformaldehyde, cryoprotected, sectioned 40
mm-thick, and collected at 150-mm intervals. Six sections per brain were
analyzed and consecutive sections of cortex were used for Ab andGFAP stain-
ing. Vectastain kit (Vector Laboratories) were used to perform Ab and GFAP
staining according to manufacturer’s directions. Thionin staining was per-
formed as described (Pozniak et al., 2002). For Ab and GFAP stainings,
6E10 (Covance) and GFAP (Abcam) antibodies were used, respectively. The
plaque numbers, the sizes of the plaques, and GFAP staining were quantified
using NIH ImageJ program.
Western Blotting and Immunoprecipitation
Mouse brains were homogenized in RIPA buffer (50mMTris-HCl pH: 8.0, 1mM
EDTA, 0.1% SDS, 150 mM NaCl, 1% NP40, 0.1% sodium-deoxycholate)
including Complete Protease Inhibitor mixture (Roche), centrifuged, 100 mg
of the supernatant was loaded onto 4%–15% gradient SDS-PAGE gels and
immunoblotted with anti-SIRT1 (Upstate), 6E10, APPa, APPb, APP C-terminal
(Covance, Figure 3F), APP C-terminal (Santa Cruz, Figure 3H), ADAM10,
ADAM10-Prodomain, ADAM9, ADAM17, Aph1a, Aph1b, Pen2, Rock1, NICD,
p-t Ser399, RARa, RARb, RXR, LXR (Abcam), Presenilin1 (Cell Signaling),
and Ac-K (Immuno-chem) antibodies. In order to separate the APPa fragment
from APP (Figure 3E), 10%–20%SDS-PAGE gels were used and run for 2.5 hr.
For western blotting using cells, cells were harvested and extracted in RIPA
buffer as explained above. Proteosome inhibitors were used when analyzing
NICD. Western blotting experiments were performed with at least three mice
from each genotype and age and representative data are shown.
The immunoprecipitations were carried out by using Pierce Direct IP Kit
(Thermo Scientific). Immobilizing the antibody covalently to agarose beads,
this method results in purified antigen free from antibody contamination To
show the endogenous interaction between SIRT1 and RARb, anti-SIRT1 anti-
body or normal rabbit serum (NRS) was coupled to beads, and then WT and
SIRT1/ (SIRT1/) MEFs were incubated with the beads. To determine
RARb acetylation, anti-RARb antibody or NRS was coupled to beads, and
then WT, SIRT1/ (SIRT1/), SIRT1/ overexpressing SIRT1-HY, and
SIRT1-overexpressing (mSIRT1) MEFs were incubated with the beads. The
eluate was blotted with anti-SIRT1, anti-RARb, and anti-Ac-K antibodies.
Fear Conditioning
10-15 mice from each indicated genotype and age were trained and tested in
a fear conditioning device containing one observation chamber (30 3 24 3
21 cm; MED-Associates, Inc.). Fear to the tone was assessed by measuring
freezing behavior. The output from video camera mounted in the chamber
was fed into a video processor, and the mice were videotaped throughout
each of the sessions. Freezing behavior, defined as the absence of all move-
ments except for the breathing, was scored by the computer program.
Freezing was quantified by computing the percentage of observations in which
the mouse had been scored as freezing during test. The experimenter was
blind to the genotypes and ages of the mice.
Morris Water Maze
Morris water maze testing procedure has been described previously (Bryan
et al., 2009; Cao et al., 2007). Six to 12 mice from each indicated genotype
and age were trained to find the visible platform three trials a day for the first
day and tested to find the hidden platform for 7 consecutive days. In each trial,
the mice were allowed to swim until it found the hidden platform, or until 2 min
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had elapsed and, at which point the mouse was guided to the platform. The
mouse was then allowed to sit on the platform for 10 s before being picked
up. During the test days, the platform was hidden 1 cm beneath the water.
The escape latency was recorded by a video camera. The experimenter was
blind to the genotypes and ages of the mice. The swim speed of each mouse
was calculated by video tracking system and MATLAB software.
ELISA and Secretase Activity Assays
Ab 1–42 and Ab 1–40 levels of brain tissue were quantitated by using Ab 1–42
and Ab 1–40 ELISA kits (Biosource), respectively. Phosphorylation levels of p-t
Ser199 was quantitated by using ELISA (Sigma). a- and b-secretase activities
were quantitated by using a- and b-secretase activity assay kits (R&D
Systems), respectively. Ab 1–42 levels of the conditioned media from
APPswe/PSEN1dE9 cells were measured by using Ab 1–42 ELISA kit (Bio-
source). All ELISA and secretase activity assays were performed according
to the manufacturer’s directions.
RNA Isolation and Analysis
Total RNA from mouse brains was isolated by using Trizol (QIAGEN). For real
time q-PCR analysis, cDNA was synthesized from total RNA by SuperScript III
reverse transcriptase (Invitrogen) with random primers. The cDNA was then
subjected to PCR analysis with gene specific primers in the presence of
CYBR green (Bio-Rad). Relative abundance ofmRNAwas obtained by normal-
ization to 18S levels.
Chromatin Immunoprecipitation Analysis
Chromatin immunoprecipitation (CHIP) analysis from mouse brains was per-
formed usingMagnaChip kit (Millipore) according tomanufacturer’s directions
by using SIRT1 antibody (Upstate) and IgG. The primer sequences for
proximal fragment are as the following: primer 1 forward, AGAAGCCGAAA
GCCCTTCT; primer 1 reverse, GAGCGCTCTTTTCCCTGTG; primer 2 forward,
AGGCCAATCCCTGCTC TC; primer 2 reverse, GACGGCACCCAATACACTC;
primer 3 forward, TATCGCGGC TAAAATCATGG; primer 3 reverse, CTAC
CCCGAAGCTGTCAAGA; primer 4 forward, GGCCTCGCGAGTGTATTG;
primer 4 reverse, CTTCCCTGCCCTCGCT CT; upstream primer 1 forward,
CAAACCCCAGGCTCTGTTTA; upstream primer 1 reverse, CAGGACCTCTGG
AAG AGCAG; upstream primer 2 forward, CCAGCAACC ACATGGTGA;
upstream primer 2 reverse, TTGATCTTTTGGGT TTGTTTCTC; upstream
primer 3 forward, GAGAAACAAACCCAAAAGATCAA; and upstream primer 3
reverse, CCCTCTCCCAGGGTTCTCT.
Cells and Transfection
The plasmids pBABE-mSIRT1 and SIRT1+/+ and SIRT1/ MEFs have been
described (Rockenstein et al., 2005). N2A cells were from ATCC. N2A cells
stably overexpressing APPswe and PSEN1dE9 were kindly provided by
Hyo-Jin Park and Seong Hun Kim (University of Florida). The plasmids
expressing mSIRT1 and mSIRT1-HY were purchased from Addgene. Three
SIRT1-shRNA plasmids and three ADAM10-shRNA plasmids were purchased
from Open Biosystems. Transfections were performed by using Effectene
transfection reagent (QIAGEN). ADAM10-shRNA sequences used were
CCAGGAGAGTCTAAGAACTTA (shRNA 1), CAGCTCTA TATCCAGACAGAT
(shRNA2), GAGTTATCAAATGGGACACAT (shRNA3), or siRNA (GCACAAAGU
CUUAGAAUAUUU) for the 30 UTR. ADAM10-ORF clone was purchased from
Open Biosystems and siRNA against ADAM10 30 UTR was purchased from
Thermo Scientific. siRNA and ADAM10-ORF plasmid were cotransfected
with DharmaFECT Duo transfection reagent from Thermo Scientific. Via
PCR, silent mutations were introduced within the ADAM10 protein coding
region (WT shRNA1 target: CCA GGA GAG TCT AAG AAC TTA; mutant
shRNA1 target: CCC GGT GAA AGC AAA AAT CTC) to render the gene resis-
tant to shRNA 1. Cells were treated with RA (Sigma) and LE 135 (Axon Med-
chem) of final concentration 1 mM and 5 mM, respectively as described
(Li et al., 1999; Dolle´ et al., 1990).
Luciferase Assay
The plasmid expressing RARE-luciferase was purchased from Addgene. Cells
were cotransfected with RARE-luciferase reporter and pRL-TK (Renilla lucif-
erase; Promega), 24 hr later treated with RA and LE-135 for additional 48 hr.
ET
RLuciferase activity was then measured by using the Dual-Luciferase Reporter
Assay System (Promega). The final GL (firefly luciferase) activity was normal-
ized to RL (Renilla luciferase) activity. The experiments were performed in trip-
licates and were repeated three times.
Statistical Analysis
The analysis was performed using Student’s t test, and significant differences
are demonstrated by single asterisk (*) indicating p < 0.01. Error bars in figures
represent SEM.
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